MIT family translocation renal cell carcinoma
MONDO:0017886MiT family translocation renal cell carcinoma (t-RCC) is a rare subtype of renal cell carcinoma with recurrent genetic abnormalities, harboring rearrangements of the TFE3 (Xp11 t-RCC) or TFEB [t(6;11) t-RCC] genes. The t(6;11) t-RCC has distinctive histologic features of biphasic appearance with larger epitheloid and smaller eosinophilic cells. The symptoms are usually non-specific and include hematuria, flank pain, palpable abdominal mass and/or systemic symptoms of anemia, fatigue and fever.
Also known as: carcinoma associated with MITF/TFE translocation, translocation renal cell carcinoma
2782 clinical trials for this condition and its sub-types, 6 tagged with MIT family translocation renal cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of MIT family translocation renal cell carcinoma
-
TFEB-rearranged renal cell carcinoma 0 trials
-
New cocktail of three drugs shows promise for tough kidney cancers
Disease control Recruiting nowThis phase 2 study is testing whether a combination of three drugs—sasanlimab, palbociclib, and axitinib—can shrink tumors or slow the growth of advanced kidney cancer. The trial will enroll 25 adults with clear cell or translocation renal cell carcinoma that has spread. Research…
Phase 2 • Sponsor: Stephanie Berg • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug cocktail aims to fight kidney cancer when immunotherapy fails
Disease control Recruiting nowThis study tests whether combining two oral drugs, abemaciclib and cabozantinib, is safe and effective for people with advanced clear cell or translocation kidney cancer that has already been treated with immunotherapy. The trial has two phases: first, finding the best dose with …
Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for rare cancers: immunotherapy drug targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…
Phase 2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC